RxDoctor Payments Data

Francesco Rotatori, MD

Cardiovascular Disease · Staten Island, NYNPI 1902127814

Payments from drug & device makers

$57,634in general payments, 2019–2025

Across 378 payments — averaging $152.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$50K
  • Johnson & Johnson$1K
  • Astrazeneca UK Limited$863
  • AstraZeneca$655
  • Abiomed$636
  • Novartis$621
  • plus $4K from 33 others

What the payments were for

  • Speaking & faculty fees$27,88575%
  • Food & beverage$9,13725%
  • Education$970%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,634 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$255,798
Medicare patients
664
Services billed
2,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$108,618
EntrestoSacubitril/Valsartan66$64,625
XareltoRivaroxaban44$62,405
Repatha SureclickEvolocumab47$55,170
MultaqDronedarone Hcl18$19,646
FarxigaDapagliflozin Propanediol18$19,524
NexletolBempedoic Acid13$8,148
JanumetSitagliptin Phos/Metformin Hcl13$7,216
Rosuvastatin Calcium250$5,253
Metoprolol Succinate273$3,399
Atorvastatin Calcium159$2,045
Ranolazine ErRanolazine21$1,647
Icosapent Ethyl11$1,490
Losartan Potassium100$790
Valsartan34$763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$203$108,61897 claims
NovartisEntresto$621$64,62566 claims
Johnson & JohnsonXarelto$1,056$62,40544 claims
Sanofi-aventis U.S. LLCMultaq$24$19,64618 claims
AstraZenecaFarxiga$655$19,52418 claims
Esperion Therapeutics, Inc.Nexletol$139$8,14813 claims
MerckJanumet$288$7,21613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →